Latest Updates of Companies in the Drug Delivery Nanoparticles Formulation Market
| Company | Headquarters | Latest Update |
| Well Shield & Crystalplex | India | Researchers have developed ion-pair stealth shields that allow nanoparticles to bypass the body's immune defences. |
| TRANSFERRA Nanosciences Inc. | Canada | It remains to leverage Transferra's expertise in producing challenging lipid nanoparticles for RNA-driven therapies. |
| DIANT Pharma | United States | In September 2025, DIANT Pharma, Inc. and RNAV8 Bio announced a strategic partnership to provide biopharma organizations with an integrated path from mRNA sequence design via scalable lipid nanoparticle (LNP) manufacturing. |
| Ipsen & Insmed | United States | Ipsen has focused strongly on long-acting recombinant technology. |
| Bristol-Myers Squibb | New Jersey | Bristol Myers Squibb has agreed to acquire Orbital Therapeutics, a confidentially held biotechnology organization pioneering a novel generation of RNA medicines that reprogram the immune system in vivo. |
Recent Developments in the Drug Delivery Nanoparticles Formulation Market
- In October 2025, Gelteq Limited, a clinical and science-based organization specialising in gel-based oral delivery solutions, announced it had started a preclinical animal trial evaluating its proprietary formulation technology for oily and poorly soluble medicines.
- In January 2025, Evonik is partnering with ST Pharm, an organization that manufactures active ingredients for gene therapy, to increase its RNA and nucleic acid therapeutic services. Through the partnership, Evonik offers customized nucleic acids from ST Pharm alongside its portfolio of lipid and lipid nanoparticle (LNP) drug product development solutions.
Supply Chain Analysis
R&D:
- Research and development (R&D) in drug delivery nanoparticle formulation includes pre-formulation and design, formulation synthesis approaches, physicochemical characterization, stability assessment, in vitro performance evaluation, and scaling and regulatory processes.
- Key Players: Well Shield & Crystalplex
Manufacturing Processes:
- Manufacturing processes for drug delivery nanoparticles involve two main approaches: bottom-up, such as assembling molecules, and top-down, such as reducing bulk size.
- Key Players: DIANT Pharma and TRANSFERRA Nanosciences Inc.
Patient Services:
- Patient services in the drug delivery nanoparticles formulation include enhancing therapeutic effectiveness, safety, and compliance via targeted delivery, controlled release, and enhanced bioavailability.
- Key Players:Bristol-Myers Squibb and Ipsen & Insmed
Market Growth
The global drug delivery nanoparticles formulation market size was estimated at USD 92.6 billion in 2025 and is predicted to increase from USD 105.38 billion in 2026 to approximately USD 337.31 billion by 2035, expanding at a CAGR of 13.8% from 2026 to 2035.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking